



(11) **EP 2 641 601 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 31/573 ^(2006.01) **A61K 31/454** ^(2006.01)
A61K 31/69 ^(2006.01) **A61K 39/395** ^(2006.01)
A61P 35/00 ^(2006.01) **A61K 45/06** ^(2006.01)

(48) Corrigendum issued on:
21.09.2016 Bulletin 2016/38

(45) Date of publication and mention
of the grant of the patent:
06.07.2016 Bulletin 2016/27

(21) Application number: **13168383.1**

(22) Date of filing: **07.08.2007**

(54) **Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib**

Verfahren zur Behandlung von Multiplem-Myelomen mit Hilfe von Kombinationstherapien auf Basis von HuLuc63 und Bortezomib

Procédés de traitement du myélome multiple à l'aide de polythérapies à base de HuLuc63 et bortezomib

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR**
Designated Extension States:
HR

(30) Priority: **07.08.2006 US 836185 P**
15.06.2007 US 944262 P

(43) Date of publication of application:
25.09.2013 Bulletin 2013/39

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
07840746.7 / 2 068 874

(73) Proprietors:
• **AbbVie Biotherapeutics Inc.**
Redwood City, CA 94063 (US)
• **Dana-Farber Cancer Institute, Inc.**
Boston, MA 02215 (US)

(72) Inventors:
• **Afar, Daniel**
Fremont, California 94555 (US)
• **Andersen, Kenneth C.**
Wellesley, Massachusetts 02482 (US)
• **Tai, Yu-Tzu**
Newton, Massachusetts 02459 (US)

(74) Representative: **Roques, Sarah Elizabeth et al**
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(56) References cited:
US-A1- 2005 025 763 US-A1- 2006 024 296

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).